- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
370 CHAPTER 8 Stone disease
Kidney stone treatment options: watchful waiting
The traditional indications for intervention are pain, infection, and obstruction. Hematuria caused by a stone is only very rarely severe or frequent enough to be the only reason to warrant treatment.
Before embarking on treatment of a stone that you think is the cause of the patient’s pain or infections, warn the patient that though you may be able to remove the stone successfully, their pain or infections may persist (i.e., the stone may be coincidental to their pain or infections, which may be due to something else).
Remember, UTIs are common in women, as are stones, and it is not therefore surprising that the two may coexist in the same patient but be otherwise unrelated.
Options for stone treatment are watchful waiting, extracorporeal shock wave (ESWL), flexible ureteroscopy, percutaneous nephrolithotomy (PCNL), open surgery, and medical dissolution therapy.
When to watch and wait—and when not to
It is not necessary to treat every kidney stone. As a rule of thumb, the younger the patient, the larger the stone, and the more symptoms it is causing, the more inclined we are to recommend treatment.
Thus, one would probably do nothing about a 1 cm asymptomatic stone in the kidney of a 95-year-old patient. On the other hand, a 1 cm stone in an asymptomatic 20-year-old runs the risk over the remaining (many) years of the patient’s life of causing problems. It could drop into the ureter, causing ureteric colic, or it could increase in size and affect kidney function or cause pain.
Asymptomatic stones followed over a 3-year period are more likely to require intervention (surgery or ESWL) or to increase in size or cause pain if they are >4 mm in diameter and if they are located in a middle or lower pole calyx.1 The approximate risks, over 3 years of follow-up, of requiring intervention, of developing pain, or of increase in stone size, relative to stone size, is shown in Table 8.3.
Another factor determining the need for treatment is the patient’s job. Airline pilots are not allowed to fly if they have kidney stones, for fear that the stones could drop into the ureter at 30,000 ft, with disastrous consequences.
Some stones are definitely not suitable for watchful waiting. Untreated struvite (i.e., infection related) staghorn calculi will eventually destroy the kidney if untreated and are a significant risk to the patient’s life. Watchful waiting is therefore NOT recommended for staghorn calculi unless patient comorbidity is such that surgery would be a higher risk than watchful waiting.
1 Burgher A, et al. (2004). Progression of nephrolithiasis: long-term outcomes with observation of asymptomatic calculi. J Endourol 18:534–539.
KIDNEY STONE TREATMENT OPTIONS: WATCHFUL WAITING 371
Table 8.3 Approximate 3-year risk of intervention, pain, or increase in stone size
|
|
|
Stone size |
|
|
|
|
|
|
|
<5 mm |
5–10 mm |
11–15 mm |
>15 mm |
|
|
|
|
|
% Requiring |
20% |
25% |
40% |
30% |
intervention |
|
|
|
|
% Causing pain |
40% |
40% |
40% |
60% |
% Increasing |
50% |
55% |
60% |
70% |
in size |
|
|
|
|
|
|
|
|
|
Historical series suggest that ~30% of patients with staghorn calculi who did not undergo surgical removal died of renal-related causes—renal failure and urosepsis (septicemia, pyonephrosis, perinephric abscess).2,3 A combination of a neurogenic bladder and staghorn calculus seems to be particularly associated with a poor outcome.4
2 Blandy JP, Singh M (1976). The case for a more aggressive approach to staghorn stones. J Urol 115:505–506.
3 Rous SN, Turner WR (1977). Retrospective study of 95 patients with staghorn calculus disease. J Urol 118:902.
4 Teichmann J (1995). Long-term renal fate and prognosis after staghorn calculus management. J Urol 153:1403–1407.
372 CHAPTER 8 Stone disease
Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
The technique of focusing externally generated shock waves at a target (the stone) was first used in humans in 1980. The first commercial lithotriptor, the Dornier HM3, became available in 1983.1 ESWL revolutionized kidney and ureteric stone treatment.
Three methods of shock wave generation are commercially available— electrohydraulic, electromagnetic, and piezoelectric.
Electrohydraulic
Application of a high-voltage electrical current between 2 electrodes about 1 mm apart under water causes discharge of a spark. Water around the tip of the electrode is vaporized by the high temperature, resulting in a rapidly expanding gas bubble. The rapid expansion and then rapid collapse of this bubble generates a shock wave that is focused by a metal reflector shaped as a hemi-ellipsoid.
This method was used in the original Dornier HM3 lithotriptor.
Electromagnetic
Two electrically conducting cylindrical plates are separated by a thin membrane of insulating material. Passage of an electrical current through the plates generates a strong magnetic field between them, the subsequent movement of which generates a shock wave. An acoustic lens is used to focus the shock wave.
Piezoelectric
A spherical dish is covered with about 3000 small ceramic elements, each of which expands rapidly when a high voltage is applied across them. This rapid expansion generates a shock wave. X-ray, ultrasound, or combinations of both are used to locate the stone on which the shock waves are focused.
Older machines required general or regional anesthesia because the shock waves were powerful and caused severe pain.
Newer lithotriptors generate less powerful shock waves, allowing ESWL with oral or parenteral analgesia in many cases, but they are less efficient at stone fragmentation.
Efficacy of ESWL
The likelihood of fragmentation with ESWL depends on stone size and location, anatomy of renal collecting system, degree of obesity, and stone composition. ESWL is most effective for stones <2 cm in diameter, in favorable anatomical locations. It is less effective for stones >2 cm diameter, in lower-pole stones in a calyceal diverticulum (poor drainage), and those composed of cystine or calcium oxalate monohydrate (very hard).
Stone-free rates for solitary kidney stones are 80% for stones <1 cm in diameter, 60% for those between 1 and 2 cm, and 50% for those >2 cm in diameter. Lower stone-free rates as compared with open surgery or PCNL are accepted because of the minimal morbidity of ESWL.
1 Chaussy CG, Brendel W, Schmidt E (1980). Extracorporeal induced destruction of kidney stones by shock waves. Lancet 2:1265–1268.
STONE FRAGMENTATION TECHNIQUES: ESWL 373
There have been no randomized studies comparing stone-free rates between different lithotriptors. In nonrandomized studies, rather surprisingly, when it comes to efficacy of stone fragmentation, older (the original Dornier HM3 machine) is better (but with higher requirement for analgesia and sedation or general anesthesia). Less powerful (modern) lithotriptors have lower stone-free rates and higher retreatment rates.
Side effects of ESWL
ESWL causes a certain amount of structural and functional renal damage (found more frequently the harder you look). Hematuria (microscopic, macroscopic) and edema are common, perirenal hematomas less so (0.5% detected on ultrasound with modern machines, although reported in as many as 30% with the Dornier HM3).
Effective renal plasma flow (measured by renography) has been reported to fall in ~30% of treated kidneys. There are data suggesting that ESWL may increase the likelihood of development of hypertension.
Acute renal injury may be more likely to occur in patients with preexisting hypertension, prolonged coagulation time, coexisting coronary heart disease, or diabetes and in those with solitary kidneys.
Contraindications to ESWL
Absolute contraindications are pregnancy and uncorrected blood clotting disorders (including anticoagulation).
Procedure-specific consent form: potential complications after ESWL
Common
-Bleeding on passing urine for short period after procedure
-Pain in the kidney as small fragments of stone pass after fragmentation
-UTI from bacteria released from the stone, needing antibiotic treatment.
Occasional
-Stone will not break as too hard, requiring an alternative treatment
-Repeated ESWL treatments may be required
-Recurrence of stones
Rare
-Kidney damage (bruising) or infection, needing further treatment
-Stone fragments occasionally get stuck in the tube (ureter) between the kidney and the bladder, requiring hospital admission and sometimes surgery to remove the stone fragment
-Severe infection requiring intravenous antibiotics and sometimes drainage of the kidney by a small drain placed through the back into the kidney.
Alternative therapy
Endoscopic surgery, open surgery, or observation can be used to allow spontaneous passage.